BridgeBio announced positive Phase III results for two rare‑disease programs, delivering a double win for the company. Encaleret met primary and key secondary endpoints in autosomal dominant hypocalcemia type 1 (ADH1), with 76% of treated patients achieving predefined serum and urine calcium targets at Week 24. The company said it will pursue regulatory filing next year. BridgeBio also reported success for BBP‑418 in limb‑girdle muscular dystrophy type 2I/R9, reinforcing the firm’s strategy of advancing genetically defined rare‑disease medicines through registrational studies. Management described both programs as well tolerated and consistent with expected disease biology. The twin readouts strengthen BridgeBio’s late‑stage portfolio and create near‑term regulatory and commercialization milestones that could reshape the company’s growth trajectory.